PURPOSE: Although the 21-gene recurrence score (RS) assay has been validated to assess the risk of distant recurrence in hormone receptor-positive breast cancer patients, the relationship between RS and the risk of locoregional recurrence (LRR) remains unclear. The purpose of this study was to determine if RS is associated with LRR in breast cancer patients and whether this relationship varies based on the type of local treatment [mastectomy or breast-conserving therapy (BCT)]. METHODS: 163 consecutive estrogen receptor-positive breast cancer patients at our institution had an RS generated from the primary breast tumor between August 2006 and October 2009. Patients were treated with lumpectomy and radiation (BCT) (n = 110) or mastectomy alone (n = 53). Patients were stratified using a pre-determined RS of 25 and then grouped according to local therapy type. RESULTS: Median follow-up was 68.2 months. Patients who developed an LRR had stage I or IIA disease, >2 mm surgical margins, and received chemotherapy as directed by RS. While an RS > 25 did not predict for a higher rate of LRR, an RS > 24 was associated with LRR in our subjects. Among mastectomy patients, the 5-year LRR rate was 27.3 % in patients with an RS > 24 versus 10.7 % (p = 0.04) in those whose RS was ≤ 24. RS was not associated with LRR in patients who received BCT. CONCLUSIONS: Breast cancer patients treated with mastectomy for tumors that have an RS > 24 are at high risk of LRR and may benefit from post-mastectomy radiation.
PURPOSE: Although the 21-gene recurrence score (RS) assay has been validated to assess the risk of distant recurrence in hormone receptor-positive breast cancerpatients, the relationship between RS and the risk of locoregional recurrence (LRR) remains unclear. The purpose of this study was to determine if RS is associated with LRR in breast cancerpatients and whether this relationship varies based on the type of local treatment [mastectomy or breast-conserving therapy (BCT)]. METHODS: 163 consecutive estrogen receptor-positive breast cancerpatients at our institution had an RS generated from the primary breast tumor between August 2006 and October 2009. Patients were treated with lumpectomy and radiation (BCT) (n = 110) or mastectomy alone (n = 53). Patients were stratified using a pre-determined RS of 25 and then grouped according to local therapy type. RESULTS: Median follow-up was 68.2 months. Patients who developed an LRR had stage I or IIA disease, >2 mm surgical margins, and received chemotherapy as directed by RS. While an RS > 25 did not predict for a higher rate of LRR, an RS > 24 was associated with LRR in our subjects. Among mastectomy patients, the 5-year LRR rate was 27.3 % in patients with an RS > 24 versus 10.7 % (p = 0.04) in those whose RS was ≤ 24. RS was not associated with LRR in patients who received BCT. CONCLUSIONS:Breast cancerpatients treated with mastectomy for tumors that have an RS > 24 are at high risk of LRR and may benefit from post-mastectomy radiation.
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Skye H Cheng; Cheng-Fang Horng; Mike West; Erich Huang; Jennifer Pittman; Mei-Hua Tsou; Holly Dressman; Chii-Ming Chen; Stella Y Tsai; James J Jian; Mei-Chin Liu; Joseph R Nevins; Andrew T Huang Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: B Fisher; J Dignam; N Wolmark; A DeCillis; B Emir; D L Wickerham; J Bryant; N V Dimitrov; N Abramson; J N Atkins; H Shibata; L Deschenes; R G Margolese Journal: J Natl Cancer Inst Date: 1997-11-19 Impact factor: 13.506
Authors: B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher Journal: N Engl J Med Date: 1989-02-23 Impact factor: 91.245
Authors: Dimitry S A Nuyten; Bas Kreike; Augustinus A M Hart; Jen-Tsan Ashley Chi; Julie B Sneddon; Lodewyk F A Wessels; Hans J Peterse; Harry Bartelink; Patrick O Brown; Howard Y Chang; Marc J van de Vijver Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Gulisa Turashvili; Joanne F Chou; Edi Brogi; Monica Morrow; Maura Dickler; Larry Norton; Clifford Hudis; Hannah Y Wen Journal: Breast Cancer Res Treat Date: 2017-07-12 Impact factor: 4.872
Authors: Minji Koh; Jinhong Jung; Su Ssan Kim; Seung Do Ahn; Eun Kyung Choi; Il Yong Chung; Jong Won Lee; Sung-Bae Kim; Jae Ho Jeong Journal: Breast Cancer Res Treat Date: 2021-04-23 Impact factor: 4.872
Authors: Kamran A Ahmed; G Daniel Grass; Amber G Orman; Casey Liveringhouse; Michael E Montejo; Hatem H Soliman; Heather S Han; Brian J Czerniecki; Javier F Torres-Roca; Roberto Diaz Journal: Int J Breast Cancer Date: 2018-06-10
Authors: Kamran A Ahmed; Casey L Liveringhouse; Matthew N Mills; Nicholas B Figura; G Daniel Grass; Iman R Washington; Eleanor E Harris; Brian J Czerniecki; Peter W Blumencranz; Steven A Eschrich; Jacob G Scott; Roberto Diaz; Javier F Torres-Roca Journal: EBioMedicine Date: 2019-08-12 Impact factor: 11.205
Authors: David Krug; René Baumann; Wilfried Budach; Marciana Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer Journal: Breast Care (Basel) Date: 2020-01-24 Impact factor: 2.860
Authors: David D Yang; Daniela L Buscariollo; Angel M Cronin; Shicheng Weng; Melissa E Hughes; Richard J Bleicher; Adam L Cohen; Sara H Javid; Stephen B Edge; Beverly Moy; Joyce C Niland; Antonio C Wolff; Michael J Hassett; Rinaa S Punglia Journal: Radiat Oncol Date: 2020-08-17 Impact factor: 3.481